Drug Profile

Iganidipine

Alternative Names: NKY 722

Latest Information Update: 21 Sep 2010

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kyoto Pharmaceutical Industries; Senju Pharmaceutical
Developer ISTA Pharmaceuticals
Class Antihypertensives; Piperazines; Pyridines
Mechanism of Action Calcium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Glaucoma

Most Recent Events

21 Sep 2010 Discontinued - Phase-I for Glaucoma in USA (Ophthalmic)
14 May 2009 Phase I development is ongoing in USA
21 Jun 2006 Iganidipine has been licensed to ISTA Pharmaceuticals in North America

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com